Monthly archive | PharmaTutor

27 May 2026

Interviews for Production, QA, QC, Packing and Microbiology at EUGIA

Join a leading pharmaceutical company committed to quality, compliance and patient safety.

27 May 2026

Fresher Pharma and Science Openings at Ipca Laboratories

For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents.

27 May 2026

Walk in Drive for Quality Control at Gufic Biosciences

M. Pharm / B. Pharm / M.Sc / B.Sc ; Knowledge of Instruments like HPLC, UPLC, GC, UV, AMV

27 May 2026

Regulatory Affairs, Supply Chain Jobs at Fresenius Kabi India

Fresenius Kabi India is a global healthcare company MNC that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition.

27 May 2026

Scientists Discover How Lung Cancer Cells Change Identity to Escape Treatment

Researchers at University of Southampton have uncovered a key mechanism that allows lung cancer cells to become more aggressive and resistant to treatment by switching back to an earlier developmental state.

27 May 2026

Scientists Discover New Way to Make Immunotherapy More Effective in Breast Cancer

Researchers from Medical University of Vienna have identified a major mechanism that allows breast cancer tumours to escape the body’s immune system, opening the door for more effective immunotherapy treatments in the future.

27 May 2026

AstraZeneca’s Breast Cancer Drug Camizestrant faces US FDA Delay as Agency Seeks More Clinical Data

Pharma major AstraZeneca has received an extension in the US FDA review timeline for its investigational breast cancer therapy camizestrant, a next-generation oral selective estrogen receptor degrader (SERD) being evaluated for HR-positive, HER2-negative advanced breast cancer with ESR1 mutations.

27 May 2026

AstraZeneca-Daiichi’s Datroway Wins US Approval for Aggressive Breast Cancer

AstraZeneca and Daiichi Sankyo have announced that the U.S. Food and Drug Administration (FDA) has approved DATROWAY (datopotamab deruxtecan-dlnk) for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. The approval makes DATROWAY the first TROP2-directed antibody-drug conjugate (ADC) approved in the United States for first-line treatment in this patient population.

26 May 2026

Research Career for Pharma, Biotechnology, Life Sciences at NIPER

First class post-graduate degree such as M.S. (Pharm)/ M.Pharm / MSc / M.Tech or Equivalent (with specialization in Pharmaceutics/ Pharmacology & Toxicology / Biotechnology/ Life Sciences